Gene sequencing platform IDs new biomarkers for pancreatic cancer survival

Nov. 8, 2012
Genomic and pharmacogenomic diagnostic tests developer Skuldtech used its gene sequencing platform to identify new biomarkers for pancreatic cancer treatment during a phase III clinical trial.

Genomic and pharmacogenomic diagnostic tests developer Skuldtech (Montpellier, France) used its gene sequencing platform to identify new biomarkers for pancreatic cancer treatment during a phase III clinical trial.

These survival markers were identified during a clinical study, whose purpose was to evaluate the therapeutic efficiency of a new treatment combining pharmaceutical company AB Science (Paris, France)'s masitinib and gemcitabine, compared to the current standard pancreatic cancer treatment of gemcitabine only. Patents have been filed to protect the markers, which are also associated with the masitinib marketing authorization application already filed with regulatory authorities by AB Science.

Based on its technological approach associating gene sequencing with its proprietary bioinformatic tools and gene profiling studies (transcriptome) on blood samples, Skuldtech has identified several sets of blood biomarkers associated with the different groups of patients treated in this phase III clinical trial.

To reach this objective, the first part of the protocol was to collect a blood sample from each patient before treatment, establish its transcriptome, and associate it with the patient's clinical progress. Then, significant bioinformatic and biostatistical processing enabled the isolation of biological markers associated with each patient group, with patients grouped according to their overall survival. These biomarkers will be used for developing future diagnostics that will help choose the treatment and establish clinical prognostics for patients.

Based on the same technological approach, Skuldtech also filed two new patents in 2012. The first, filed in February, is related to predictive blood markers for four-year survival in patients with chronic myelomonocytic leukemia (CMML). The second, filed in September, is related to predictive blood markers for an inflammatory joint disease.

-----

Follow us on Twitter, 'like' us on Facebook, and join our group on LinkedIn

Laser Focus World has gone mobile: Get all of the mobile-friendly options here.

Subscribe now to BioOptics World magazine; it's free!

Sponsored Recommendations

Brain Computer Interface (BCI) electrode manufacturing

Jan. 31, 2025
Learn how an industry-leading Brain Computer Interface Electrode (BCI) manufacturer used precision laser micromachining to produce high-density neural microelectrode arrays.

Electro-Optic Sensor and System Performance Verification with Motion Systems

Jan. 31, 2025
To learn how to use motion control equipment for electro-optic sensor testing, click here to read our whitepaper!

How nanopositioning helped achieve fusion ignition

Jan. 31, 2025
In December 2022, the Lawrence Livermore National Laboratory's National Ignition Facility (NIF) achieved fusion ignition. Learn how Aerotech nanopositioning contributed to this...

Nanometer Scale Industrial Automation for Optical Device Manufacturing

Jan. 31, 2025
In optical device manufacturing, choosing automation technologies at the R&D level that are also suitable for production environments is critical to bringing new devices to market...

Voice your opinion!

To join the conversation, and become an exclusive member of Laser Focus World, create an account today!